Kesin Pharma Logo (Kesin Logo)
Topiramate Solution
Product Images NDC 81033-035
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 81033-035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Kesin Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Topi-25-b (Topi 25 B)
This is a label for a medication called Topiramate Oral Solution, containing 25 mg of ganate per mL. The medication is recommended for oral use only and comes in a 473 mL bottle. The label provides details such as NDC number, storage instructions, and instructions for dispensing the medication to patients including an oral dosing syringe and a medication guide. The product is manufactured by ASCEND Laboratories Ltd in India and distributed by ASCEND Laboratories, LLC in Bedminsi, New Jersey.*
Topi-25mg-120ml-cart (Topi 25mg 120ml Cart)
This is a description for a pharmaceutical product called Topiramate Oral Solution. It is intended for oral use only and should be dispensed with an oral dosing syringe and a medication guide. The product comes in a 120mL volume and is ready to use. The storage temperature should be between 20°C to 25°C (66°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). The medication should be kept out of reach of children, and the container seal should be intact before use. Unused portions should be discarded within 60 days of opening. The product is manufactured by Alkem Laboratories Ltd. in India and distributed by Ascend Laboratories, LLC in the USA. For more information, a visit to the company's website is recommended.*
Topi-fig-1 (Topi Fig 1)
This data table shows the comparison of Topiramate 50 mg/day and Topiramate 400 mg/day for the treatment of seizures based on the cumulative rates for time to the first seizure. The study included 234 participants for the 50 mg/day group and 236 participants for the 400 mg/day group. The results indicate a statistically significant difference (p=0.0002) between the two groups over time (in days) in terms of time to the first seizure.*
Topi-fig-2 (Topi Fig 2)
This text contains information about a study comparing the effects of Topiramate at different doses and a placebo on a group of participants. The study data includes the number of participants in each group, the period rate, and the change from baseline to the double-blind phase. The results of the study were likely statistically significant, as indicated by the p-values provided (*p<0.010, **p<0.001).*
Topi-stru (Topi Stru)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
